Below are our currently enrolling studies for patients with psoriatic arthritis.
Sponsor: UCB Biopharma SRL
Protocol Number: PA0016
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: Takeda
Protocol Number: TAK-279-PsO-3003
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: Eli Lilly and Company
Protocol Number: I1F-MC-RHDE
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
Detailed Information:
To learn more or see if you qualify: Click Here